Jacobs Journal of Cancer Science and Research

Sprouty Proteins and Cancer

*Samar Masoum Moghaddam
Department Of Surgery, University Of New South Wales, Australia

*Corresponding Author:
Samar Masoum Moghaddam
Department Of Surgery, University Of New South Wales, Australia

Published on: 2014-05-19

Abstract

Sprouty proteins are inducible modulators of mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) pathway that regulate key cellular functions, including cell vitality, differentiation and motility. Owing to their critical regulatory functions, Sprouty proteins are well documented to participate in developmental and adult physiological processes and, consistently, to be implicated in the regulation of pathological conditions, including cancer. Since discovery in Drosophila in 1998.

Keywords

Proteins;Cancer;Biomarker

Introduction

Sprouty proteins are inducible modulators of mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) pathway that regulate key cellular functions, including cell vitality, differentiation and motility. Owing to their critical regulatory functions, Sprouty proteins are well documented to participate in developmental and adult physiological processes and, consistently, to be implicated in the regulation of pathological conditions, including cancer. Since discovery in Drosophila in 1998, four human homologs of Sprouty have been identified, among which Spry1, Spry2 and Spry4 have been reported to be deregulated in a variety of malignant conditions. A growing body of evidence shows that the expression of Sprouty inhibits cancer cell proliferation, migration, invasion and survival. Since these cellular functions are central to growth and development of malignancies, the clinicopathological significance of the Sprouty expression has been studied by different investigators for the past decade. Accordingly, the following clinical applications are among those suggested for the expression of Sprouty proteins in malignant tumors